查詢結果分析
相關文獻
- Life-threatening Hypoxemia in a Young Adult: A Case Report of Idiopathic Acute Eosinophilic Pneumonia
- 急重症高齡肺炎的抗生素選擇
- 照顧一位肺炎併發急性呼吸衰竭病人成功脫離呼吸器之護理經驗
- 成人水痘肺炎合併急性呼吸衰竭--病例報告及文獻回顧
- Non-invasive Ventilation and Acute Respiratory Failure of Interstitial Lung Disease: A Case Report
- Antimicrobial Susceptibility Testing for Klebsiella Pneumoniae Isolates Resistant to Extended-Spectrum β-Lactam Antibiotics
- Swyer James Syndrome Following Mycoplasma Pneumoniae Pneumonia: Report of One Case
- Klebsiella Pneumoniae Liver Abscess in Childhood--A Case Report
- Acute Respiratory Distress Syndrome in Mycoplasma Pneumonia: A Case Report and Review
- 退伍軍人肺炎症與臭氧設備水處理方式之研討
頁籤選單縮合
題 名 | 急重症高齡肺炎的抗生素選擇=Antibiotic of Choice in an Emergency and Critical Care Elderly Patient with Pneumonia |
---|---|
作 者 | 汪忠炫; 黃美嫆; 黃炳文; 黃金鈴; | 書刊名 | 臺灣急診專科醫師期刊 |
卷 期 | 4:1 2012.03[民101.03] |
頁 次 | 頁6-14 |
分類號 | 418.281 |
關鍵詞 | 肺炎; 急性呼吸衰竭; Pneumonia; Acute respiratory failure; Doripenem; Gram(-) bacilli; Pseudomonas aeruginosa; |
語 文 | 中文(Chinese) |
中文摘要 | 肺炎在2010年65歲以上老年人十大死因排第三名。抗藥性日益增多,醫院常見難治療Gram(-)菌困擾著臨床醫師對抗生素藥物選擇是否採用升階治療。因此評估carbapenam屬的新藥(doripenem)使用在老年病人療效及安全性。以回溯性方法收集2010年10月至2011年10月加護病房170位65歲以上病人使用doripenem治療及85位65歲以上急性呼吸衰竭患者,以SPSS 17進行資料分析。結果doripenem治療後病人存活率71.2%(121/170),WBC及CRP其P值<0.05具統計上意矣。115位肺炎及肺炎合併其他感染,存活率72.2%(83/115),發現fever其P值<0.05。比較doripenem(n=40)與1evofloxacin(n=45)在急性呼吸衰竭療效,發現WBC及CRP其p值<0.05;存活率62.5% vs. 71.1%。研究發現重症感染治癒率高(71.2%),醫院常見Gram(-)茵引起難治療感染,新藥doripenem提供另一治療Gram(-)菌藥物選項。 |
英文摘要 | Pneumonia was the third leading cause of death Taiwan in 2010 for people over 65 or elder. Intractable infections caused by Gram-negative pathogens are common in hospital. New drugs are urgently needed to combat this threat. The aim of this article is to investigate the resistance and therapeutic effect of doripenem in the Critical Care Unit. A retrospective case review of 170 elderly patients treated with doripenem and 85 elderly patients with acute respiratory failure receiving intubations in our Critical Care Unit from 2010 October to 2011 October. The survival rate was 71.2% (121/170) after treatment with doripenem. The white blood cell count (WBC) and C-reactive protein (CRP) level were significantly different with before doripenem treatment compared with after doripenem treatment (p-value<0.05). The survival rate of patients with pneumonia was 72.2% (83/115). In patients with acute respiratory failure receiving intubations the survival rate for those treated with doripenem group was 62.5% versus 71.1% at levofloxacin group. Doripenem is a significant new drug in the treatment of hospitalized patients with serious bacterial infections. |
本系統中英文摘要資訊取自各篇刊載內容。